Premium
Biosimilars in the EU: a new guide for health professionals
Author(s) -
Chaplin Steve
Publication year - 2017
Publication title -
prescriber
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.106
H-Index - 3
eISSN - 1931-2253
pISSN - 0959-6682
DOI - 10.1002/psb.1617
Subject(s) - biosimilar , medicine , health professionals , european commission , agency (philosophy) , commission , alternative medicine , health care , family medicine , european union , international trade , law , pathology , finance , business , philosophy , epistemology , political science
With the number of biosimilar drugs being approved in the EU rising rapidly, the European Medicines Agency and the European Commission have jointly published a guide for healthcare professionals to provide reassurance on their safety and efficacy – but does it fall short of the rigorous analysis clinicians require?